View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

AtaiBeckley (NasdaqGM: ATAI) reported peer reviewed Phase 2a results for its BPL-003 program in treatment resistant depression. The study showed a rapid and sustained antidepressant response from a ...

AtaiBeckley Inc. (NASDAQ:ATAI) secured a spot on our list of the best penny stocks set to explode. AtaiBeckley Inc.

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health ...

Loop Capital initiated coverage of the stock with a buy rating. atai has several therapies in late-stage trials but no marketed drugs yet. The company said it has enough cash to fund operations ...

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...

Clinical stage biopharma company atai Life Sciences ATAI announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient (drug delivery) ...